ClinVar Miner

Submissions for variant NM_001540.5(HSPB1):c.407G>T (p.Arg136Leu) (rs863225022)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Athena Diagnostics Inc RCV000201072 SCV000255780 pathogenic Charcot-Marie-Tooth disease axonal type 2F 2015-07-17 criteria provided, single submitter clinical testing
GeneDx RCV000236739 SCV000292874 likely pathogenic not provided 2016-02-03 criteria provided, single submitter clinical testing The R136L variant has been reported previously in association with CMT2 and dHMN in two unrelated individuals (Capponi et al., 2011) and with CMT2F/dHMN in multiple affected family members (Stancanelli et al., 2014). Additionally, a different amino acid substitution at the same position (R136W) and many nearby missense variants have been published in association with HSPB1-related disorders (Stenson et al., 2014), supporting the functional importance of this region of the protein. The R136L variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R136L variant is a non-conservative amino acid substitution, which occurs at a position that is conserved across species, and in silico analysis predicts this substitution is probably damaging to the protein structure/function. Therefore, this variant is likely pathogenic
Ambry Genetics RCV000622699 SCV000741123 pathogenic Inborn genetic diseases 2015-11-23 criteria provided, single submitter clinical testing
Invitae RCV000201072 SCV000832663 pathogenic Charcot-Marie-Tooth disease axonal type 2F 2019-09-13 criteria provided, single submitter clinical testing This sequence change replaces arginine with leucine at codon 136 of the HSPB1 protein (p.Arg136Leu). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and leucine. This variant is not present in population databases (ExAC no frequency). This variant has been observed to segregate with features of Charcot-Marie-Tooth, type 2 (CMT2) disease and distal hereditary motor neuropathy (dHMN) in affected families (PMID: 25547330, 21611841). This variant has also been reported in additional, unrelated individuals affected with CMT2 and dHMN (PMID: 22176143, 26989944). ClinVar contains an entry for this variant (Variation ID: 217230). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C65"). This variant disrupts the p.Arg136 amino acid residue in HSPB1. Other variant(s) that disrupt this residue have been observed in individuals with HSPB1-related conditions (PMID: 15122254, 22521462, 20178975), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.
Molecular Genetics Laboratory,London Health Sciences Centre RCV000789060 SCV001337300 pathogenic Charcot-Marie-Tooth disease criteria provided, single submitter clinical testing
Inherited Neuropathy Consortium RCV000789060 SCV000928409 uncertain significance Charcot-Marie-Tooth disease no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.